Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 10Fallopian Tube Neoplasms 10Breast Neoplasms 7Endometrial Neoplasms 5Neoplasms 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Pheochromocytoma 2Paraganglioma 2Osteosarcoma 2Neuroendocrine Tumors 2Neuroblastoma 2Metastatic Castration-resistant Prostate Cancer 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Glioma 2Glioblastoma 2Ependymoma 2Cholangiocarcinoma 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1

Interventions

olaparib 1decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
BRCA1 Mutation × olaparib × 30 days × Clear all
NCT06177171 2026-05-27

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

University of California, San Francisco

Phase 1 Recruiting
18 enrolled

BRCA1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡